Larin Fe 1.5/30

Endometriosis, Low Testosterone, Osteoporosis + 16 more

Treatment

20 Active Studies for Larin Fe 1.5/30

What is Larin Fe 1.5/30

Norethisterone

The Generic name of this drug

Treatment Summary

Norethisterone (also known as norethindrone) is a synthetic form of the hormone progestogen. This hormone is commonly prescribed to treat irregular menstrual periods, endometriosis, and used as part of contraception and hormone replacement therapy. Norethisterone was first developed in 1951 and used as an oral contraceptive in 1962. It is a more powerful form of progesterone than the body produces naturally.

Necon

is the brand name

image of different drug pills on a surface

Larin Fe 1.5/30 Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Necon

Norethisterone

1967

347

Effectiveness

How Larin Fe 1.5/30 Affects Patients

Norethisterone is a synthetic hormone taken either for contraception or to treat hormone-related conditions. It works similarly to the body's natural progesterone but is much more powerful. Norethisterone acts in the pelvis to change how the cervix and uterus work, as well as by blocking hormones that affect the development of eggs. There is a slight increase in the risk of breast cancer when using this medication, so it is important that patients be aware of this risk and do regular self-examinations.

How Larin Fe 1.5/30 works in the body

Norethisterone is a hormone that affects the reproductive system. It thickens the cervical mucus to stop sperm from entering the uterus and thins the endometrium so a fertilized egg cannot implant. Norethisterone also works to decrease the hormones that cause an egg to be released from an ovary. This helps to prevent pregnancy. Additionally, when used as part of hormone replacement therapy in menopausal women, norethisterone can protect against endometrial hyperplasia, which is linked to an increased risk of cancer. Norethisterone does not have a major effect on other steroid receptors like

When to interrupt dosage

The recommended dosage of Larin Fe 1.5/30 hinges upon the diagnosed condition, such as Atrophic, Fracture and Hormone Replacement Therapy. The amount of dosage fluctuates, based on the method of administration (e.g. Oral or Tablet) featured in the table below.

Condition

Dosage

Administration

Fracture

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch - Transdermal, Tablet, chewable, Tablet, chewable - Oral, Patch, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Osteoporosis

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch - Transdermal, Tablet, chewable, Tablet, chewable - Oral, Patch, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Atrophic

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch - Transdermal, Tablet, chewable, Tablet, chewable - Oral, Patch, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

hypoestrogenism

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch - Transdermal, Tablet, chewable, Tablet, chewable - Oral, Patch, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Hot flashes

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch - Transdermal, Tablet, chewable, Tablet, chewable - Oral, Patch, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Birth Control

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch - Transdermal, Tablet, chewable, Tablet, chewable - Oral, Patch, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Therapeutic procedure

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch - Transdermal, Tablet, chewable, Tablet, chewable - Oral, Patch, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Endometriosis

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch - Transdermal, Tablet, chewable, Tablet, chewable - Oral, Patch, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Menopause

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch - Transdermal, Tablet, chewable, Tablet, chewable - Oral, Patch, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Estrogen Deprivation Symptoms

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch - Transdermal, Tablet, chewable, Tablet, chewable - Oral, Patch, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Oral Contraceptives

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch - Transdermal, Tablet, chewable, Tablet, chewable - Oral, Patch, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Low Testosterone

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch - Transdermal, Tablet, chewable, Tablet, chewable - Oral, Patch, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Osteoporosis, Postmenopausal

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch - Transdermal, Tablet, chewable, Tablet, chewable - Oral, Patch, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Endometriosis

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch - Transdermal, Tablet, chewable, Tablet, chewable - Oral, Patch, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Primary Ovarian Insufficiency

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch - Transdermal, Tablet, chewable, Tablet, chewable - Oral, Patch, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Hormonal Contraception

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch - Transdermal, Tablet, chewable, Tablet, chewable - Oral, Patch, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

female castration

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch - Transdermal, Tablet, chewable, Tablet, chewable - Oral, Patch, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Hormone Replacement Therapy

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch - Transdermal, Tablet, chewable, Tablet, chewable - Oral, Patch, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Vasomotor System

0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg

, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch - Transdermal, Tablet, chewable, Tablet, chewable - Oral, Patch, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Warnings

Larin Fe 1.5/30 has 8 prohibitions; therefore, it should not be consumed in conjunction with the conditions stipulated in the following table.

Larin Fe 1.5/30 Contraindications

Condition

Risk Level

Notes

Liver Diseases

Do Not Combine

Thrombophilia

Do Not Combine

Vaginal Hemorrhage

Do Not Combine

Malignant Neoplasms

Do Not Combine

Benign hepatic neoplasm

Do Not Combine

Breast Cancer

Do Not Combine

Thromboembolism

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Norethisterone may interact with Pulse Frequency

There are 20 known major drug interactions with Larin Fe 1.5/30.

Common Larin Fe 1.5/30 Drug Interactions

Drug Name

Risk Level

Description

Astemizole

Major

The metabolism of Astemizole can be decreased when combined with Norethisterone.

Axitinib

Major

The metabolism of Axitinib can be decreased when combined with Norethisterone.

Cabazitaxel

Major

The metabolism of Cabazitaxel can be decreased when combined with Norethisterone.

Clomipramine

Major

The metabolism of Clomipramine can be increased when combined with Norethisterone.

Copanlisib

Major

The metabolism of Copanlisib can be decreased when combined with Norethisterone.

Larin Fe 1.5/30 Toxicity & Overdose Risk

The lowest toxic dose of oral contraceptives in mice has been found to be 6g/kg, and the lowest dose in women is 42mg/kg. There are no reports of serious side effects from taking too much of these contraceptives, even in children. Symptoms of overdose may include severe nausea and vomiting.

image of a doctor in a lab doing drug, clinical research

Larin Fe 1.5/30 Novel Uses: Which Conditions Have a Clinical Trial Featuring Larin Fe 1.5/30?

160 active clinical trials are presently assessing the potential of Larin Fe 1.5/30 to provide Birth Control, Atrophic and Testosterone Replacement Therapy.

Condition

Clinical Trials

Trial Phases

Birth Control

21 Actively Recruiting

Not Applicable, Phase 3, Phase 4, Early Phase 1, Phase 2

Oral Contraceptives

1 Actively Recruiting

Not Applicable

Endometriosis

30 Actively Recruiting

Early Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4

Osteoporosis

28 Actively Recruiting

Not Applicable, Phase 4, Phase 1, Phase 3, Phase 2

Low Testosterone

5 Actively Recruiting

Phase 4, Phase 2, Phase 1

Endometriosis

2 Actively Recruiting

Phase 4, Not Applicable

Hot flashes

19 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Early Phase 1, Phase 3

Estrogen Deprivation Symptoms

0 Actively Recruiting

Osteoporosis, Postmenopausal

0 Actively Recruiting

female castration

0 Actively Recruiting

Atrophic

5 Actively Recruiting

Phase 4, Not Applicable

Hormone Replacement Therapy

0 Actively Recruiting

Hormonal Contraception

0 Actively Recruiting

hypoestrogenism

1 Actively Recruiting

Phase 4

Fracture

0 Actively Recruiting

Vasomotor System

0 Actively Recruiting

Primary Ovarian Insufficiency

0 Actively Recruiting

Therapeutic procedure

0 Actively Recruiting

Menopause

0 Actively Recruiting

Larin Fe 1.5/30 Reviews: What are patients saying about Larin Fe 1.5/30?

5

Patient Review

10/20/2014

Larin Fe 1.5/30 for Birth Control

This medicine helped me to regulate my heavy periods, but I found that it also made me feel constantly tired, upset, and caused me to gain weight. I'm not sure if all the side effects are worth it.

5

Patient Review

1/31/2017

Larin Fe 1.5/30 for Birth Control

I unfortunately experienced some negative side effects like rashes and headaches. My blood pressure also increased.

4.7

Patient Review

1/25/2019

Larin Fe 1.5/30 for Painful Periods

I switched to this treatment after my old one stopped being effective and I started having painful cycles again. So far, no negative side effects that I've noticed. The packaging could be better designed--the pills sometimes pop out too forcefully and it's easy to drop them.

4

Patient Review

8/22/2019

Larin Fe 1.5/30 for Abnormally Long or Heavy Periods

I was pretty tired and felt nauseous the first week I took Larin Fe 1/20. However, I've been spotting on and off since then and it's a vast improvement from my natural period (which involved gushing and heavy flow). So overall, I'm pleased.

4

Patient Review

8/22/2019

Larin Fe 1.5/30 for Abnormally Long or Heavy Periods

I was pretty tired and nauseous the first week I took Larin Fe 1/20, but it was worth it. I barely need a liner now when I'm on my period, which is such a huge improvement from before.

3.7

Patient Review

9/29/2014

Larin Fe 1.5/30 for Abnormal Bleeding from the Uterus

Though this medication has largely stopped my heavy bleeding, I still experience some spotting every day. Additionally, I have high blood pressure for which I take three separate medications. The only reaction that I know of so far from taking Larin FE is rashes. My right eye was blind for at least one minute. Then the right side of head hurts and my nostril. I don't know what caused this.

3.7

Patient Review

5/9/2014

Larin Fe 1.5/30 for Abnormally Long or Heavy Periods

3.7

Patient Review

2/17/2018

Larin Fe 1.5/30 for Birth Control

This treatment is effective with no negative side effects that I've experienced.

3

Patient Review

4/2/2015

Larin Fe 1.5/30 for Acne

Really didn't have any negative effects from this. Only good things to report!

3

Patient Review

9/5/2022

Larin Fe 1.5/30 for Abnormally Long or Heavy Periods

I've been on this birth control for a month and it's helped with my period. I get migraines every day, but hopefully that will go away after a few more months.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about larin fe 1.5/30

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Larin 1.5 30 A combination pill?

"The LARINTM 1.5/30 is a hormonal contraceptive that contains a combination of the progestogen and estrogen."

Answered by AI

What kind of birth control is Larin Fe?

"Larin 24 Fe is a combination oral contraceptive containing active tablets with norethindrone acetate (progestin) and ethinyl estradiol (estrogen), and placebo tablets with ferrous fumarate (un medically active ingredient)."

Answered by AI

What are the side effects of Larin Fe 1.5 30?

"The following are possible side effects: feeling nauseous, vomiting, abdominal cramps and bloating, spotting, changes in menstrual flow, skin discoloration, breast tenderness or enlargement, nipple discharge."

Answered by AI

Does Larin Fe 1.5 30 prevent pregnancy?

"The Larin Fe 1.5/30 pill is taken by women who want to prevent pregnancy and is an oral contraceptive. Oral contraceptives are very effective in preventing pregnancy."

Answered by AI

Clinical Trials for Larin Fe 1.5/30

Image of VA Greater Los Angeles Healthcare System, West Los Angeles, CA in West Los Angeles, United States.

EBQI Strategies for Women's Health

Any Age
All Sexes
West Los Angeles, CA

Women Veterans are the fastest growing segment of VA users, with most users in midlife. This dramatic growth has created challenges for VA to ensure that appropriate services are available to meet women Veterans' needs, and that they will want and be able to use those services. Furthermore, few VA improvement efforts have focused on women Veterans' health and health care in midlife. The EMPOWER QUERI 3.0 Program is a cluster randomized type 3 hybrid implementation-effectiveness trial testing two strategies designed to support implementation and sustainment of evidence-based practices for women Veterans in at least 18 VA facilities from 4 regions.

Waitlist Available
Has No Placebo

VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Alison B Hamilton, PhD MPH

Image of UC San Diego in San Diego, United States.

Epione Device for Bone Conditions

18+
All Sexes
San Diego, CA

The goal of this investigational device exemption is to evaluate the Epione assistance for introducer placement during percutaneous procedures in musculo-skeletic (MSK) structures of the pelvis and the spine in adults. The main question is the determination of the rate of feasible procedures assisted by the Epione device Participants will undergo their procedure(s) as planned by their physician. If they accept to participate to the study, the differences with standard of care will be: * The use of the Epione device to place the introducer(s), instead of freehand placement if they do not participate * Additional CT or CBCT scans during the procedure.

Waitlist Available
Has No Placebo

UC San Diego (+2 Sites)

Sean Tutton, MD

Quantum Surgical

Image of University of Waterloo in Waterloo, Canada.

Virtual Chiropractic Intervention for Spinal Fracture

18+
All Sexes
Waterloo, Canada

This study will determine feasibility of a chiropractor delivered virtual intervention for individuals following osteoporotic vertebral fracture. This pilot trial will have two parallel groups with a 1:1 ratio. Participants will be randomized to: 1) immediate receipt; or 2) waitlist usual care control and delayed receipt of VIVA 10 weeks post-randomization. VIVA is an intervention for people with vertebral fractures that covers four areas: pain management, safe movement, exercise, and nutrition. It includes print and video resources, and a framework for goal setting, selecting exercises, and teaching body mechanics. A chiropractor (DC) completes a virtual assessment and then leads twelve 1:1 virtual sessions (via Zoom) over eight weeks. Sessions start with brief education on a topic (e.g., safe movement, pain management, exercise, nutrition), followed by training and modeling of exercise and safe movement strategies, then goal setting, and action planning. This trial will be considered feasible if a) we recruit 14 people in eight months; b) 80% of participants complete the trial; and c) exercise adherence is 75%.

Recruiting
Has No Placebo

University of Waterloo

Have you considered Larin Fe 1.5/30 clinical trials?

We made a collection of clinical trials featuring Larin Fe 1.5/30, we think they might fit your search criteria.
Go to Trials
Image of Erevna Innovations Inc. in Montreal, Canada.

Sculptra + Restylane for Post-Menopausal Skin Concerns

40 - 65
Female
Montreal, Canada

The post-menopausal state is marked by a sharp decline in estrogen, leading to significant structural and functional changes in the skin, including collagen loss, dryness, thinning, and reduced elasticity. To address these concerns, aesthetic injectables products such as Sculptra® Aesthetic (poly-L-lactic-acid \[PLLA- SCA\]) and Restylane Skinboosters®\[HASBV\] (small-particle hyaluronic acid - SP-HA) can be used. PLLA-SCA stimulates collagen production via cellular activation (biostimulator), gradually improving dermal structure. HASBV enhances hydration, elasticity, and skin texture when injected under the skin. Considering that hydration and laxity represent the primary aesthetic concerns in this patient population. Targeted treatment with SP-HA (HASBV) to improve hydration and PLLA-SCA to address laxity have been shown to produce significant clinical outcomes by directly addressing these key dermal deficiencies. This approach forms the basis of the current study.

Phase 4
Recruiting

Erevna Innovations Inc.

Andreas Nikolis, MD, PhD

Image of University Hospitals Cleveland Medical Center in Cleveland, United States.

Ketamine for Pelvic Pain

18 - 89
Female
Cleveland, OH

The purpose of this research study is to see if ketamine infusion during surgery can decrease pain after surgery. Ketamine is a medication commonly used as part of anesthesia during surgery and is approved by the US FDA. Patients will be randomized to either receive standard anesthesia with OR without ketamine. The surgical procedure will be the same regardless of which group patients are randomized to. After surgery, patients will be asked to rate their pain in the post-operative observation unit and at their two-week post-operative visit. No additional visits are required for participation in this study. The investigators estimate the surveys will take approximately 10 minutes to complete.

Phase 4
Waitlist Available

University Hospitals Cleveland Medical Center

Morgan Cheeks, MD

Have you considered Larin Fe 1.5/30 clinical trials?

We made a collection of clinical trials featuring Larin Fe 1.5/30, we think they might fit your search criteria.
Go to Trials

Have you considered Larin Fe 1.5/30 clinical trials?

We made a collection of clinical trials featuring Larin Fe 1.5/30, we think they might fit your search criteria.
Go to Trials